Cargando…

Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA

Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression, having the capacity to drive higher protein expression compared to mRNA as it replicates wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldon, Yoann, McKay, Paul F., Moreno Herrero, Jorge, Vogel, Annette B., Lévai, Réka, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Haas, Heinrich, Fábián, Katalin, Le Grand, Roger, Sahin, Ugur, Shattock, Robin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463288/
https://www.ncbi.nlm.nih.gov/pubmed/34589271
http://dx.doi.org/10.1016/j.omtn.2021.06.008
_version_ 1784572370297552896
author Aldon, Yoann
McKay, Paul F.
Moreno Herrero, Jorge
Vogel, Annette B.
Lévai, Réka
Maisonnasse, Pauline
Dereuddre-Bosquet, Nathalie
Haas, Heinrich
Fábián, Katalin
Le Grand, Roger
Sahin, Ugur
Shattock, Robin J.
author_facet Aldon, Yoann
McKay, Paul F.
Moreno Herrero, Jorge
Vogel, Annette B.
Lévai, Réka
Maisonnasse, Pauline
Dereuddre-Bosquet, Nathalie
Haas, Heinrich
Fábián, Katalin
Le Grand, Roger
Sahin, Ugur
Shattock, Robin J.
author_sort Aldon, Yoann
collection PubMed
description Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression, having the capacity to drive higher protein expression compared to mRNA as it replicates within the cytoplasm. In this study, we examined the potential of stabilized native-like HIV-1 Envelope glycoprotein (Env) trimers to elicit immune responses when delivered by saRNA polyplexes (PLXs), assembled with linear polyethylenimine. We showed that Venezuelan equine encephalitis virus (VEEV) saRNA induces a stronger humoral immune response to the encoded transgene compared to Semliki Forest virus saRNA. Moreover, we characterized the immunogenicity of the soluble and membrane-bound ConSOSL.UFO Env design in mice and showed a faster humoral kinetic and an immunoglobulin G (IgG)2a skew using a membrane-bound design. The immune response generated by PLX VEEV saRNA encoding the membrane-bound Env was then evaluated in larger animal models including macaques, in which low doses induced high IgG responses. Our data demonstrated that the VEEV saRNA PLX nanoparticle formulation represents a suitable platform for the delivery of stabilized HIV-1 Env and has the potential to be used in a variety of vaccine regimens.
format Online
Article
Text
id pubmed-8463288
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-84632882021-09-28 Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA Aldon, Yoann McKay, Paul F. Moreno Herrero, Jorge Vogel, Annette B. Lévai, Réka Maisonnasse, Pauline Dereuddre-Bosquet, Nathalie Haas, Heinrich Fábián, Katalin Le Grand, Roger Sahin, Ugur Shattock, Robin J. Mol Ther Nucleic Acids Original Article Self-amplifying mRNA (saRNA) represents a promising platform for nucleic acid delivery of vaccine immunogens. Unlike plasmid DNA, saRNA does not require entry into the nucleus of target cells for expression, having the capacity to drive higher protein expression compared to mRNA as it replicates within the cytoplasm. In this study, we examined the potential of stabilized native-like HIV-1 Envelope glycoprotein (Env) trimers to elicit immune responses when delivered by saRNA polyplexes (PLXs), assembled with linear polyethylenimine. We showed that Venezuelan equine encephalitis virus (VEEV) saRNA induces a stronger humoral immune response to the encoded transgene compared to Semliki Forest virus saRNA. Moreover, we characterized the immunogenicity of the soluble and membrane-bound ConSOSL.UFO Env design in mice and showed a faster humoral kinetic and an immunoglobulin G (IgG)2a skew using a membrane-bound design. The immune response generated by PLX VEEV saRNA encoding the membrane-bound Env was then evaluated in larger animal models including macaques, in which low doses induced high IgG responses. Our data demonstrated that the VEEV saRNA PLX nanoparticle formulation represents a suitable platform for the delivery of stabilized HIV-1 Env and has the potential to be used in a variety of vaccine regimens. American Society of Gene & Cell Therapy 2021-06-24 /pmc/articles/PMC8463288/ /pubmed/34589271 http://dx.doi.org/10.1016/j.omtn.2021.06.008 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Aldon, Yoann
McKay, Paul F.
Moreno Herrero, Jorge
Vogel, Annette B.
Lévai, Réka
Maisonnasse, Pauline
Dereuddre-Bosquet, Nathalie
Haas, Heinrich
Fábián, Katalin
Le Grand, Roger
Sahin, Ugur
Shattock, Robin J.
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title_full Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title_fullStr Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title_full_unstemmed Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title_short Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
title_sort immunogenicity of stabilized hiv-1 env trimers delivered by self-amplifying mrna
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463288/
https://www.ncbi.nlm.nih.gov/pubmed/34589271
http://dx.doi.org/10.1016/j.omtn.2021.06.008
work_keys_str_mv AT aldonyoann immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT mckaypaulf immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT morenoherrerojorge immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT vogelannetteb immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT levaireka immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT maisonnassepauline immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT dereuddrebosquetnathalie immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT haasheinrich immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT fabiankatalin immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT legrandroger immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT sahinugur immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna
AT shattockrobinj immunogenicityofstabilizedhiv1envtrimersdeliveredbyselfamplifyingmrna